Back to News
Market Impact: 0.3
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Source: GlobeNewswire
Healthcare & BiotechCapital Returns (Dividends / Buybacks)Company Fundamentals
Alaunos Therapeutics priced a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes. The financing improves near-term liquidity but is likely dilutive to existing shareholders, creating a modest negative share-price overhang.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
TCRT-0.35
More News
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- Flock Offers Employees Buyouts as Customers Flee
- Anthropic’s first embedded evaluator is … Accenture?
- Volkswagen and Porsche Holding cut outlook
- Warren Buffett steps down as Berkshire Hathaway chairman
- Meet Warren Buffett’s son Howard, a former sheriff, war photographer, and now, Berkshire’s new chairman
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Hebbia Alternatives: A Workflow-Based Buyer’s Guide
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect